Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

Detalles Bibliográficos
Autores principales: Gulácsi, László, Brodszky, Valentin, Baji, Petra, Rencz, Fanni, Péntek, Márta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427141/
https://www.ncbi.nlm.nih.gov/pubmed/28447267
http://dx.doi.org/10.1007/s12325-017-0538-3
_version_ 1783235610862944256
author Gulácsi, László
Brodszky, Valentin
Baji, Petra
Rencz, Fanni
Péntek, Márta
author_facet Gulácsi, László
Brodszky, Valentin
Baji, Petra
Rencz, Fanni
Péntek, Márta
author_sort Gulácsi, László
collection PubMed
description
format Online
Article
Text
id pubmed-5427141
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-54271412017-05-26 Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries Gulácsi, László Brodszky, Valentin Baji, Petra Rencz, Fanni Péntek, Márta Adv Ther Erratum Springer Healthcare 2017-04-26 2017 /pmc/articles/PMC5427141/ /pubmed/28447267 http://dx.doi.org/10.1007/s12325-017-0538-3 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Erratum
Gulácsi, László
Brodszky, Valentin
Baji, Petra
Rencz, Fanni
Péntek, Márta
Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
title Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
title_full Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
title_fullStr Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
title_full_unstemmed Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
title_short Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
title_sort erratum to: the rituximab biosimilar ct-p10 in rheumatology and cancer: a budget impact analysis in 28 european countries
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427141/
https://www.ncbi.nlm.nih.gov/pubmed/28447267
http://dx.doi.org/10.1007/s12325-017-0538-3
work_keys_str_mv AT gulacsilaszlo erratumtotherituximabbiosimilarctp10inrheumatologyandcancerabudgetimpactanalysisin28europeancountries
AT brodszkyvalentin erratumtotherituximabbiosimilarctp10inrheumatologyandcancerabudgetimpactanalysisin28europeancountries
AT bajipetra erratumtotherituximabbiosimilarctp10inrheumatologyandcancerabudgetimpactanalysisin28europeancountries
AT renczfanni erratumtotherituximabbiosimilarctp10inrheumatologyandcancerabudgetimpactanalysisin28europeancountries
AT pentekmarta erratumtotherituximabbiosimilarctp10inrheumatologyandcancerabudgetimpactanalysisin28europeancountries

Ejemplares similares